National Contract for Monoclonal Antibody for Respiratory Syncytial Virus (RSV) Passive Immunisation for Infants - Pathfinder Programme 3
Awarded
The competition has ended and a winner has been selected.
- Procedure
- Without prior noticeTwo stages
- Agreement
- Buying goods
- Estimated value
- €1
Brief
The Health Service Executive (HSE) has entered into an agreement with Sanofi for the delivery of 50,000 doses of the monoclonal antibody Nirsevimab (Beyfortus®) for passive immunisation against Respiratory Syncytial Virus (RSV) in infants. This contract, valued at 1 EUR, is for a third pathfinder immunisation programme to protect babies born from March 1, 2026, to February 28, 2027, with delivery occurring in Dublin over a seven-month period during the RSV season. The purpose is to protect all babies from RSV disease, which commonly causes respiratory infections and can lead to hospitalisation in young infants.
Farmasøytisk engroshandel
Result
- SanofiWinner
- 1Number of tenders received
- €1Contract value
Custom Assessment Criteria
Get answers to your bid/no-bid criteria
Set them up once and Cobrief answers them in every tender
Will you bid?
The agent sets up the bid and writes the first draft. Free for 14 days.
Award Criteria
Description
Negotiated
Source
No source found in the documents. Check the weight against the tender documents.
Description
Negotiated with sole authorised supplier
Source
No source found in the documents. Check the weight against the tender documents.
Previous winners
Who are you up against?
The suppliers who have won similar contracts at Health Service Executive (HSE)
From the notice
In accordance with National Immunisation Advisory Committee (NIAC) advice, HSE Public Health: National Health Protection, with Access & Integration and the National Women and Infants Health Programme wish to put in place a contract for a monoclonal antibody, Nirsevimab (Beyfontus®) for a third pathfinder immunisation programme to protect all babies from RSV disease born from 1st March 2026 to 28th February 2027. RSV is a common virus that causes respiratory infections in young babies. Babies under three months old get sicker with RSV than older children. Each winter in Ireland one in two newborns babies will get RSV and many will need medical care from their GP or the emergency department of a children’s hospital. Four out of a hundred new born babies are hospitalised due to RSV with some babies needing special treatment in intensive care units. Nirsevimab is currently the best way to protect babies from RSV. This contract will supply 50,000 doses of this drug for passive immunisation over a seven month period during the RSV season.
Contact
procurement.helpdesk@hse.ie- Result · PrequalificationType
- DublinLocation
- 33651600Main codeVaccines